12 Studies on Three Simcere Zaiming Innovative Medicines to Be Presented at ESMO 2026
Inmular Approved as First Domestically Developed Long Acting RSV Prophylactic Monoclonal Antibody in China
Three Simcere Zaiming Innovative Medicines Featured in 12 Studies at ESMO 2026
Simcere Announces Strategic Partnership with Reyoung Bio to Secure Exclusive Commercialization Rights for Long-Acting RSV Monoclonal Antibody
Cosela® Receives Approval for a New Indication, Expanding Full-Cycle, Multi-Lineage Myeloprotection Across All Chemotherapy Lines for Extensive-Stage Small Cell Lung Cancer
Simcere and Schrödinger Enter Global Drug Discovery and Development Collaboration
Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis
Simcere Zaiming Announces First Patient Enrolled in Phase I Clinical Trial of Anti-LRRC15 ADC SIM0613
Simcere Zaiming Presents 9 Studies at the 2026 ASCO Annual Meeting
Simcere Zaiming’s Pan-RAS Inhibitor SIM0532 Doses First Patient in Clinical Trial